Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Current Deferred Revenue (2016 - 2025)

AC Immune (ACIU) has disclosed Current Deferred Revenue for 9 consecutive years, with $97.1 million as the latest value for Q4 2024.

  • On a quarterly basis, Current Deferred Revenue rose 62309.34% to $97.1 million in Q4 2024 year-over-year; TTM through Dec 2024 was $97.1 million, a 62309.34% increase, with the full-year FY2024 number at $97.1 million, up 63089.08% from a year prior.
  • Current Deferred Revenue was $97.1 million for Q4 2024 at AC Immune, up from $155574.9 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $97.1 million in Q4 2024 to a low of $155574.9 in Q4 2023.
  • A 5-year average of $19.8 million and a median of $609318.9 in 2022 define the central range for Current Deferred Revenue.
  • Peak YoY movement for Current Deferred Revenue: crashed 92.52% in 2020, then soared 62309.34% in 2024.
  • AC Immune's Current Deferred Revenue stood at $338483.6 in 2020, then skyrocketed by 129.73% to $777588.0 in 2021, then dropped by 21.64% to $609318.9 in 2022, then plummeted by 74.47% to $155574.9 in 2023, then skyrocketed by 62309.34% to $97.1 million in 2024.
  • Per Business Quant, the three most recent readings for ACIU's Current Deferred Revenue are $97.1 million (Q4 2024), $155574.9 (Q4 2023), and $609318.9 (Q4 2022).